YONGAN PHARMACEUTICAL(SZ:002365)2022-12-07 08:41Group 1: Market and Product Insights - Taurine prices are currently low, with competitors including Huanggang Fuchi Pharmaceutical, Jiangyin Huachang Food Additives, and Jiangsu Yuanyang Pharmaceutical, with a total production capacity of 34,000 tons [2][3] - The future market space for taurine may see slight growth, supported by the company's strong brand and market position [3] - The company has received approval for taurine effervescent tablets, with ongoing preparations for production and market promotion [4] Group 2: Financial Performance - In the third quarter, the company's operating revenue and profit both declined year-on-year, primarily due to the suspension of the ethylene oxide project, which resulted in no sales revenue [5] - The net profit attributable to shareholders for 2015 is projected to decline by 10% to 60% compared to the previous year [5] - The company is actively expanding its market channels and increasing product investment and promotion, particularly for its subsidiary, Yong'an Health [5][6] Group 3: Investment and Strategic Planning - The company has established a new investment firm, Wuhan Yaan Investment Management Co., Ltd., to manage investments in the health and elderly care sectors [4] - The board has approved a share repurchase plan, with ongoing disclosures regarding the progress of the repurchase [6] - The long-term strategic focus is on expanding into the health industry, with plans to explore new markets and cultivate new profit growth points [6]